Some patients with rectal cancer benefit from receiving chemotherapy and radiotherapy before they have an operation to remove their tumour. This trial will determine whether the addition of a second drug (irinotecan) to the standard treatment of oral chemotherapy using capecitabine and radiotherapy will result in fewer cancer recurrences (regrowth) after the operation and if patients live longer.